Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease

被引：0
|
作者：
Fiorino, G. [1 ]
Ruiz-Aguello, M. B. [2 ]
Maguregui, A. [2 ]
Nagore, D. [2 ]
Radice, S. [1 ]
Gilardi, D. [1 ]
Correale, C. [1 ]
Allocca, M. [1 ]
Furfaro, F. [1 ]
Alfieri, M. [1 ]
Martinez, A. [2 ]
Danese, S. [1 ,3 ]
机构：
[1] Humanitas Clin & Res Ctr, Dept Gastroenterol, Milan, Italy
[2] Progenika Biopharma SA, R&D Dept, Derio, Spain
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P633
引用
收藏
页码：S403 / S404
页数：2
相关论文
共 50 条
  • [41] Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
    F. Argüelles-Arias
    M. F. Guerra Veloz
    R. Perea Amarillo
    A. Vilches-Arenas
    L. Castro Laria
    B. Maldonado Pérez
    D. Chaaro
    A. Benítez Roldán
    V. Merino
    G. Ramírez
    A. Caunedo Álvarez
    M. Romero Gómez
    Digestive Diseases and Sciences, 2017, 62 : 1305 - 1312
  • [42] Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
    Argulles-Arias, F.
    Guerra Veloz, M. F.
    Perea Amarillo, R.
    Vilches-Arenas, A.
    Castro Laria, L.
    Maldonado Perez, B.
    Chaaro, D.
    Benitez Roldan, A.
    Merino, V.
    Ramirez, G.
    Caunedo Alvarez, A.
    Romero-Gomez, Manuel
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (05) : 1305 - 1312
  • [43] Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
    Nakagawa, Tomoo
    Kobayashi, Taku
    Nishikawa, Kiyohiro
    Yamada, Fumika
    Asai, Satoshi
    Sameshima, Yulcinori
    Suzuki, Yasuo
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2019, 17 (04) : 504 - 515
  • [44] Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar
    Pagnini, Cristiano
    Di Paolo, Maria Carla
    De Angelis, Giulia
    Torcolacci, Federica
    Milano, Michele
    Trinca, Daniela
    Porciello, Roberto
    Graziani, Maria Giovanna
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (08) : E83 - E84
  • [45] Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease
    Lim, Ki Jung
    Lee, So Jung
    Kim, Sunghwan
    Lee, Su Yeon
    Lee, Min Seob
    Park, Yoon A.
    Choi, Eun Jin
    Lee, Eun Beom
    Jun, Hwang Keun
    Cho, Jong Moon
    Lee, Soo Young
    Kwon, Ki Sung
    Lim, Byung Pil
    Jeon, Myung-Shin
    Shin, Eui Cheol
    Choi, Yong Sung
    Fudim, Ella
    Picard, Orit
    Yavzori, Miri
    Ben-Horin, Shomron
    Chang, Shin Jae
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (05): : 593 - 602
  • [46] Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study
    Trystram, Noemie
    Abitbol, Vered
    Tannoury, Jenny
    Lecomte, Mahaut
    Assaraf, Julie
    Malamut, Georgia
    Gagniere, Charlotte
    Barre, Amelie
    Sobhani, Iradj
    Chaussade, Stanislas
    Amiot, Aurelien
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (08) : 887 - 899
  • [47] Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
    Mazza, S.
    Fasci, A.
    Casini, V.
    Ricci, C.
    Munari, F.
    Pirola, L.
    Girelli, C.
    Lupinacci, G.
    Pastorelli, L.
    Cavallaro, F.
    O'Sed, N. Piazza
    Ferraris, L.
    Colucci, A.
    Amato, A.
    Maurizio, V.
    Fiorino, G.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S342 - S342
  • [48] Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
    Hannah A. Blair
    Emma D. Deeks
    BioDrugs, 2016, 30 : 469 - 480
  • [49] Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
    Blair, Hannah A.
    Deeks, Emma D.
    BIODRUGS, 2016, 30 (05) : 469 - 480
  • [50] Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
    F. Argüelles-Arias
    M. F. Guerra Veloz
    R. Perea Amarillo
    A. Vilches-Arenas
    L. Castro Laria
    B. Maldonado Pérez
    D. Chaaro
    A. Benítez Roldán
    V. Merino
    G. Ramírez
    A. Caunedo Álvarez
    M. Romero Gómez
    Digestive Diseases and Sciences, 2017, 62 : 2203 - 2203
12345